Market Price

87.11 

-1.82 -2.1%

as of Mar 03 '21

52 Week Range:

77.01 181.80


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 1.28
-0.15
1.40
3.90
6.54
6.93
2.70
7.46
10.76
9.00
13.24
growth rate -100.0% 100.0% 178.6% 67.7% 6.0% -61.0% 176.3% 44.2% -16.4% 47.1%
Earnings BIT -25.16
-32.18
-2.32
-121.29
-111.99
-133.66
-210.80
-261.87
-142.61
-341.95
-522.12
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -4.90
-5.80
-80.40
-2.30
-0.86
-0.86
-0.86
-0.86
-20.43
-20.43
-20.43
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -58.81
-60.71
-4.62
-93.53
-45.10
-46.30
-77.36
-76.59
-5.85
-24.54
-41.28
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -127.83
-309.20
-16.44
-156.81
-60.39
-54.88
-100.47
-101.42
-9.00
-39.74
-77.29
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -114.48
-260.15
-16.89
-153.24
-59.84
-54.01
-94.09
-94.34
-6.14
-25.13
-46.52
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 1.53
0.83
2.19
2.46
7.53
6.72
3.60
4.95
13.91
8.21
5.55
growth rate -45.8% 163.9% 12.3% 206.1% -10.8% -46.4% 37.5% 181.0% -41.0% -32.4%
Quick Ratio 1.51
0.80
2.11
2.44
7.24
5.77
3.15
4.28
12.55
7.04
4.60
growth rate -47.0% 163.8% 15.6% 196.7% -20.3% -45.4% 35.9% 193.2% -43.9% -34.7%
Leverage 2.54
1.75
1.66
1.18
1.19
1.44
1.26
1.66
1.59
2.23
growth rate -17.0% -5.1% -28.9% 0.9% 21.0% -12.5% 31.8% -4.2% 40.3%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 2.10
3.20
3.63
4.71
3.53
2.42
3.98
5.23
30.18
62.52
93.94
growth rate 52.4% 13.5% 29.7% -25.1% -31.6% 64.6% 31.5% 477.2% 107.2% 50.3%
Acct.Payable 17.09
10.27
22.68
12.41
20.23
29.69
8.47
33.83
68.09
growth rate -39.9% 120.8% -45.3% 63.1% 46.7% -71.5% 299.5% 101.3%
Cur.Assets 51.30
37.80
45.18
193.91
270.81
247.80
224.54
373.48
1,228.64
1,426.18
1,468.91
growth rate -26.3% 19.5% 329.2% 39.7% -8.5% -9.4% 66.3% 229.0% 16.1% 3.0%
Total Assets 60.00
46.00
54.37
204.99
291.57
295.03
273.78
424.10
1,307.96
1,642.08
1,822.82
growth rate -23.3% 18.2% 277.1% 42.2% 1.2% -7.2% 54.9% 208.4% 25.5% 11.0%
Cash 48.30
33.60
39.90
187.66
264.22
73.55
80.30
122.42
599.69
370.83
835.08
growth rate -30.4% 18.8% 370.3% 40.8% -72.2% 9.2% 52.5% 389.9% -38.2% 125.2%
Inventory 0.00
0.00
0.00
0.00
12.81
12.81
12.81
83.61
125.45
171.38
growth rate 0.0% 0.0% 552.5% 50.0% 36.6%
Cur.Liabilities 33.50
45.90
20.60
78.89
35.97
36.87
62.29
75.42
88.33
173.69
264.77
growth rate 37.0% -55.1% 282.9% -54.4% 2.5% 69.0% 21.1% 17.1% 96.6% 52.4%
Liabilities 36.40
48.80
23.35
81.31
44.38
47.38
83.44
87.41
518.75
609.80
1,004.64
growth rate 34.1% -52.2% 248.2% -45.4% 6.8% 76.1% 4.8% 493.4% 17.6% 64.8%
LT Debt 1.90
1.80
1.76
1.67
1.58
3.74
14.97
6.04
424.88
420.55
681.90
growth rate -5.3% -2.4% -5.1% -5.5% 137.2% 300.5% -59.6% 6,932.0% -1.0% 62.1%
Equity 23.60
-2.82
31.02
123.68
247.19
247.65
190.35
336.69
789.22
1,032.28
818.19
growth rate -100.0% 100.0% 298.8% 99.9% 0.2% -23.1% 76.9% 134.4% 30.8% -20.7%
Common Shares 16.00
19.00
22.00
24.00
34.00
40.00
42.00
49.00
59.00
66.00
74.00
growth rate 18.8% 15.8% 9.1% 41.7% 17.7% 5.0% 16.7% 20.4% 11.9% 12.1%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 0.90
0.80
1.18
0.11
2.37
25.44
3.40
5.34
12.00
61.16
59.63
growth rate -11.1% 47.3% -90.8% 2,094.4% 973.6% -86.6% 57.0% 124.7% 409.6% -2.5%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -8.80
-15.21
-23.68
-29.69
-128.54
-149.47
-245.82
-232.00
-388.66
-456.46
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.70
-0.93
-1.06
-1.31
-1.85
-3.71
-3.63
-4.34
-5.35
-5.31
-6.66
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 32.38
178.68
145.99
104.25
130.81
385.73
369.18
563.63
401.96
growth rate 451.8% -18.3% -28.6% 25.5% 194.9% -4.3% 52.7% -28.7%
FCF -11.00
-17.00
-26.00
-31.00
-68.00
-155.00
-154.00
-253.00
-253.00
-453.00
-519.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 17.60
29.40
46.99
37.33
14.22
9.76
1.25
5.42
154.58
301.03
380.83
growth rate 67.1% 59.8% -20.6% -61.9% -31.4% -87.2% 332.6% 2,751.6% 94.7% 26.5%
Op.Income -15.50
-20.90
-2.32
-121.29
-111.99
-133.66
-210.80
-261.87
-142.61
-341.95
-522.12
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT 0.00
-32.20
-2.32
-121.29
-111.99
-135.79
-220.03
-267.27
-48.63
-362.61
-713.88
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -25.20
-32.20
-2.32
-121.29
-111.99
-135.79
-220.03
-267.27
-50.69
-361.92
-715.08
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -1.62
-1.74
-0.11
-5.14
-3.31
-3.39
-5.20
-5.49
-0.86
-5.46
-9.71
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 17.60
29.40
46.99
37.33
14.22
-84.35
-144.94
-180.64
147.23
-131.10
-236.46
growth rate 67.1% 59.8% -20.6% -61.9% -100.0% 0.0% 0.0% 100.0% -100.0% 0.0%
R&D 24.40
36.00
66.86
52.40
72.91
94.23
146.39
166.11
166.11
401.84
560.91
growth rate 47.5% 85.7% -21.6% 39.1% 29.2% 55.4% 13.5% 0.0% 141.9% 39.6%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT -110.31
-220.02
-118.03
-138.35
-137.07
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 68.03
93.94
109.93
107.09
124.89
growth rate 38.1% 17.0% -2.6% 16.6%
Acct.Payable 203.61
68.09
26.60
91.66
74.53
growth rate -66.6% -60.9% 244.7% -18.7%
Cur.Assets 1,362.30
1,468.91
2,547.35
2,459.42
2,322.67
growth rate 7.8% 73.4% -3.5% -5.6%
Total Assets 1,702.47
1,822.82
2,947.39
2,883.04
2,780.66
growth rate 7.1% 61.7% -2.2% -3.6%
Cash 724.83
835.08
1,764.21
1,639.96
1,474.64
growth rate 15.2% 111.3% -7.0% -10.1%
Inventory 166.36
171.38
173.17
179.65
220.12
growth rate 3.0% 1.0% 3.7% 22.5%
Cur.Liabilities 215.86
264.77
306.43
354.90
378.39
growth rate 22.7% 15.7% 15.8% 6.6%
Liabilities 707.27
1,004.64
1,802.56
1,840.18
1,888.62
growth rate 42.0% 79.4% 2.1% 2.6%
LT Debt 436.42
681.90
687.95
694.16
700.47
growth rate 56.3% 0.9% 0.9% 0.9%
Equity 995.20
818.19
1,144.83
1,042.87
892.05
growth rate -17.8% 39.9% -8.9% -14.5%
Common Shares 74.50
0.01
0.01
0.01
0.01
growth rate -100.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 9.43
17.26
9.12
19.17
25.30
growth rate 83.0% -47.2% 110.2% 32.0%
Cash Dividends
growth rate
Cash From OA -67.43
-163.80
627.79
-107.60
-238.19
growth rate 0.0% 100.0% -100.0% 0.0%
Sale Purchase of Stock 5.18
12.03
323.82
17.58
18.79
growth rate 132.2% 2,591.8% -94.6% 6.9%
FCF -76.86
-181.05
618.67
-126.77
-263.49
growth rate 0.0% 100.0% -100.0% 0.0%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 99.04
100.11
113.67
137.36
143.92
growth rate 1.1% 13.6% 20.8% 4.8%
Op.Income -123.59
-220.02
-118.03
-138.35
-137.07
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -126.10
-234.99
-17.38
-150.80
-196.40
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -126.33
-235.70
-17.49
-150.82
-196.50
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 86.00
-138.40
-35.09
-64.50
-61.53
growth rate -100.0% 0.0% 0.0% 0.0%
R&D 133.95
223.14
136.14
188.52
190.44
growth rate 66.6% -39.0% 38.5% 1.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (16.61)

YOY Growth Grade:

F (0.11)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -20.43 -25.73 -68.63
EPS / Growth 0.0% -3.39 -0.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 33.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 11.4% 11.4%
Future PE 0.00 0.01 7.62
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.